Physician profile
Robin Scott Dibiase
NPI 1255915716
$5,110.51
in general payments reported to CMS, 2019-2025
54 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $413 · 2023: $1,386 · 2024: $1,244 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,062.56 |
| Education | $179.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $530.02 | 2022-2025 | Cabometyx |
| Janssen Biotech, INC. | $420.57 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $409.50 | 2021-2025 | |
| Astellas Pharma US INC | $344.31 | 2023-2025 | Xospata, Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $307.52 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $232.10 | 2023-2025 | Vanflyta, Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $196.17 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $140.69 | 2023-2025 | Reblozyl, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $136.72 | 2022-2025 | Iclusig, Fruzaqla |
| Incyte Corporation | $135.95 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $129.54 | 2021-2023 | Imbruvica |
| Pfizer INC. | $126.02 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2023 | Tecvayli |
| Horizon Therapeutics Plc | $122.83 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $114.12 | 2023-2025 | Lynparza, Calquence, Tagrisso |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $103.61 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.80 | 2023-2025 | Gilotrif |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.40 | 2024-2025 | Opdivo |
| Seagen INC. | $81.65 | 2021-2023 | Padcev |
| Genzyme Corporation | $79.41 | 2021-2025 | |
| Emd Serono, INC. | $61.73 | 2022-2025 | |
| Sobi, INC | $61.66 | 2022-2024 | |
| Amgen INC. | $61.59 | 2023 | Lumakras, Nplate |
| Alnylam Pharmaceuticals INC. | $57.42 | 2024 | Givlaari, Onpattro |
| Eisai INC. | $56.51 | 2021-2025 | |
| Syndax Pharmaceuticals, INC. | $51.98 | 2025 | |
| Abbvie INC. | $51.03 | 2023-2024 | |
| Lilly USA, LLC | $50.67 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Sun Pharmaceutical Industries INC. | $41.22 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $40.54 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Stemline Therapeutics INC. | $39.00 | 2024 | Orserdu |
| Springworks Therapeutics, INC. | $38.82 | 2024-2025 | Ogsiveo |
| Mirati Therapeutics, INC. | $37.20 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $36.96 | 2022-2024 | |
| Beone Medicines USA, INC. | $36.43 | 2025 | Brukinsa |
| Immunogen, INC. | $32.26 | 2023 | Elahere |
| Puma Biotechnology, INC. | $29.95 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.33 | 2025 | Libtayo |
| Taiho Oncology, INC. | $23.85 | 2025 | |
| Blueprint Medicines Corporation | $22.79 | 2023 | Ayvakit |
| Accord Healthcare, INC. | $21.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.68 | 2024 | Ultomiris |
| Kite Pharma, INC. | $19.81 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $19.27 | 2023 | Sylvant |
| Servier Pharmaceuticals LLC | $18.47 | 2025 | |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Genmab U.S., INC. | $17.91 | 2025 | Epkinly |
| Morphosys, US INC. | $16.35 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $15.85 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.65 | 2024 | Empaveli |
| Genentech USA, INC. | $14.13 | 2024 | Venclexta |
| Organon LLC | $13.78 | 2023 | Ontruzant |
| Ipsen Biopharmaceuticals, INC | $12.94 | 2023 | Onivyde, Somatuline Depot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Dibiase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.